Antibody Information

General Information of This Antibody

Antibody ID	ANI0AGHYS
Antibody Name	Peptibody C19
Synonyms	PeptibodyC19 Click to Show/Hide
Antibody Type	Fusion protein (FP)
Antibody Subtype	Humanized IgG1 Fc-peptide-C19
Antigen Name	Fibroblast growth factor receptor 1 (FGFR1)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

PeptibodyC19-PEG4-Val-Cit-MMAE [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.55 nM	High FGFR1 expression (FGFR1+++)
Method Description	Human lung cancer cell lines showing FGFR1 overexpression (NCI-H520 and NCI-H1581) was chosen and a cell line with physiological, low levels of FGFR1 (HCC95) was chosen as a control,.
In Vitro Model	Lung large cell carcinoma	NCI-H1581 cells		CVCL_1479
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	90.49 nM	High FGFR1 expression (FGFR1+++)
Method Description	Human lung cancer cell lines showing FGFR1 overexpression (NCI-H520 and NCI-H1581) was chosen and a cell line with physiological, low levels of FGFR1 (HCC95) was chosen as a control,.
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000.00 nM	Negative FGFR1 expression (FGFR1-)
Method Description	Human lung cancer cell lines showing FGFR1 overexpression (NCI-H520 and NCI-H1581) was chosen and a cell line with physiological, low levels of FGFR1 (HCC95) was chosen as a control,.
In Vitro Model	Lung squamous cell carcinoma	HCC95 cells		CVCL_5137

References

Ref 1	Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies. Mol Pharm. 2022 May 2;19(5):1422-1433.